The autoimmune, cell-mediated condition experimental allergic encephalomyelitis (EAE) is the representative model for the inflammatory central nervous system disease MS. EAE has been extensively employed to determine the efficacy of pharmacological agents that may be of ultimate use in the treatment of MS. A wide variety of drugs has been examined for activity in EAE but, over the last decade, three groups of compounds have emerged with clear and reproducible ability to modify significantly the onset and progression of the disease. The immunosuppressants, the modulators of catecholamine activity and the antineoplastic agents have convincingly altered the course of EAE and, as a consequence, provided understanding of the mechanisms of disease expression and offered further insight into the pathogenesis of MS. The article stresses the usefulness of EAE as a model to identify prospective pharmacological treatments for MS and, in particular, considers those compounds subsequently assessed for their ability to interfere with the progression of the human disease.
1 Paterson PY. (1976) Experimental autoimmune (allergic) encephalomyelitis: induction, pathogenesis, suppression. In: PA Meischer, HJ Muller-Eberhard (eds.). Textbook of ImmunopathologyGrune & Stratton: New York, pp 179–213.
2.
2 Freund J, Stern ER, Pisani TM. (1947) Isoallergic encephalomyelitis and radiculitis in guinea-pigs after one injection of brain and mycobacterium in water-in-oil emulsion. J Immunol57: 179–194.
3.
3 Bolton C, Flower RJ. (1989) The effects of the antiglucocorticoid RU38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci45: 97–104.
4.
4 Komarek A, Dietrich FM. (1971) Chemical prevention of experimental allergic encephalomyelitis in rats: a quantitative evaluation of steroids and various non-steroid drugs. Arch Int Pharmacodyn193: 249–257.
5.
5 Levine S, Sowinski R. (1980) Therapy of allergic encephalomyelitis in rats after onset of paralysis. In: AN Davison, ML Cuzner (eds) The Suppression of Experimental Allergic Encephalomyelitis and Multiple SclerosisAcademic Press: London; pp 199–209.
6.
6 Arnon T, Teitelbaum D. (1993) Immunomodulation of experimental allergic encephalomyelitis. Is J Med Sci29: 175–181.
7.
7 Bornstein MB, et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl J Med317: 408–414.
8.
8 Fridkis-Hareli M, et al. (1994) Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigen-presenting cells — specificity and promiscuity. Proc Natl Acad Sci USA91: 4872–4876.
9.
9 Cash E, et al. (1994) Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol153: 4258–4267.
10.
10 Leonard JP, Waldburger KE, Goldman SJ. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med181: 381–386.
11.
11 Rott O, Fleischer B, Cash E. (1994) Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol24: 1434–1440.
12.
12 Ruddle NH, et al. (1990) An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med172: 1193–1200.
13.
13 Borel JF, Feurer C, Magnee C, Staehelin H. (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions6: 468–475.
14.
14 Bolton C, Cuzner ML. (1980) Modification of EAE by nonsteroidal anti-inflammatory drugs In: Davison AN, Cuzner ML, (ed.). The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis.Academic Press: London; pp 189–197.
15.
15 Bolton C, et al. (1982) Immunosuppression by cyclosporin A of experimental allergic encephalomyelitisJ Neurol Sci56: 147–153.
16.
16 Bolton C, Allsopp G, Cuzner ML. (1982) The effect of cyclosporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin Exp Immunol47: 127–132.
17.
17 Hinrichs DJ, Wegmann KW, Peters BA. (1983) The influence of cyclosporin A on the development of actively induced, passively transferred experimental allergic encephalomyelitis. Cell Immunol77: 202–209.
18.
18 Borel JF, Gubler HV, Hiestand PC, Wenger RM. (1986) Immunopharmacological properties of cyclosporine (Sandimmune), (Val2)-dihydrocyclosporine, their prospect in chronic inflammation. Adv Inflamm Res11: 277–291.
19.
19 Pender MP, Stanley GP, Yoong G, Nguyen. (1990) The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord, treatment with cyclosporin A. Acta Neuropathol80: 79–183.
20.
20 Polman CH, et al. (1988). Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol17: 209–216.
21.
21 Begley DJ, et al. (1990) Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem55: 1222–1230.
22.
22 Lemaire M, Pardridge WM, Chaudhuri G. (1988) Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharmacol Exp Ther224: 740–743.
23.
23 Paul C, Bolton C. (1994) Restoration of blood-brain barrier integrity by dexamethasone and cyclosporin A combined-dose therapy during experimental allergic encephalomyelitis. J Neuroimmunol54: 188.
24.
24 Paul C, Bolton C. (1995) Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A.Int J Immunopharm (in press).
25.
25 Feurer C, Chow LH, Borel JF. (1988) Preventive, therapeutic effects of cyclosporin, valine2-dihydro-cyclos-porin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Immunol63: 219–233.
26.
26 Reiber H, Suckling AJ. (1986) Cyclosporin A treatment of experimental allergic encephalomyelitis: Changes in immunological regulation, blood-CSF barrier function. J Neuroimmunol12: 121–130.
27.
27 Suckling AJ, Baron PW, Reiber H. (1986) CR-EAE: cyclosporin A treatment of relapsing, remitting disease. J Clin Lab Immunol21: 173–176.
28.
28 Rumjanek VM, Leyton J, Morely J. (1984) Mononuclear cell accumulation, plasma protein extravasation (PPE) during induction, remission, re-challenge of experimental allergic encephalomyelitis in the rat. J Neurol Sci65: 81–92.
29.
29 Rudge P, et al. (1989) Randomised double-blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatr52: 559–565.
30.
30 The Multiple Sclerosis Study Group. (1990) Efficacy, toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial.Ann Neurol27: 591–605.
31.
31 Kappos L. (1988) Clinical trials of immunosuppression, immunomodulation in multiple sclerosis. J Neuroimmunol20: 261–268.
32.
32 Kappos L, et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multi-centre study. Ann Neurol23: 56–63.
33.
33 Kerman RH, Wolinsky JS, Nath A, Sears ES Jr. (1988) Serial immune evaluation of cyclosporine-, placebo-treated multiple sclerosis patients. J Neuroimmunol18: 325–331.
34.
34 Calder VL, et al. (1987) Effects of cyclosporin A on expression of IL-2, IL-2 receptors in normal, MS patients. Clin Exp Immunol70: 570–577.
35.
35 Ruutianen J, et al. (1991) Treatment of acute exacerbations in early multiple sclerosis: cyclosporin A or prednisolone. Acta Neurol Scand83: 52–54.
36.
36 Trotter JL, Van DerVeen RC, Clifford DB. (1990) Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of ‘bursts’, effect of cyclosporine. J Neuroimmunol28: 9–14.
37.
37 Steck AJ, Regli F, Ochsner F, Gauthier G. (1990) Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical, immunological evaluation. Eur Neurol30: 224–228.
38.
38 Martel RR, Klicius J, Galet S. (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol55: 48–51.
39.
39 Inamura N, et al. (1988) Immunosuppressive effect offK-506 on experimental allergic encephalomyelitis in rats. Int J Immunopharmacol10: 991–995.
40.
40 Bolton C. (1991) The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following co-culture with FK-506, cyclosporin A or prednisolone. Transplant Proc23: 3375–3376.
41.
41 Bolton C. (1992) The efficacy of cyclosporin A, FK-506, prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis. Agents Actions35: 79–84.
42.
42 Deguchi K, et al. (1991) Effects offK506 on acute experimental allergic encephalomyelitis in the rat. Transplant Proc23: 3360–3362.
43.
43 Chang JY, Sehgal SN, Bansbach CC. (1991) FK506, rapamycin: novel pharmacological probes of the immune response. Trends Pharm Sci12: 218–223.
44.
44 Fruman DA, Burakoff SJ, Bierer BE. (1994) Immunophilins in protein folding, immunosuppression. FASEB8: 391–400.
45.
45 Schreiber SL, et al. (1991) Immunophilin-ligand complexes as probes of intracellular signalling pathways. Transplant Proc23: 2839–2844.
46.
46 Gershon RK, Askenase PW, Gershon MD. (1975) Requirement for vasoactive amines in delayed-type hypersensitivity. J Exp Med142: 732–747.
47.
47 Leonard JP, Mackenzie FJ, Patel HA, Cuzner ML. (1990) Splenic noradrenergic, adrenocorticoid responses during the preclinical, clinical stages of adoptively transferred experimental allergic encephalomyelitis. (EAE). J Neuroimmunol26: 183–186.
48.
48 Leonard JP, Mackenzie FJ, Patel HA, Cuzner ML. (1991) Hypothalamic noradrenergic pathways exert an influence on neuroendocrine, clinical status in experimental allergic encephalomyelitis. Brain Behav Immunol5: 328–338.
49.
49 Mackenzie FJ, Leonard JP, Cuzner ML. (1989) Changes in lymphocyte β-adrenergic receptor density, noradrenaline content of the spleen are early indicators of immune reactivity in acute experimental allergic encephalomy elitis in the Lewis rat. J Neuroimmunol23: 93–100.
50.
50 Wesselmann V, et al. (1987) Altered splenic catecholamine concentrations during experimental allergic encephalomyelitis. Pharmacol Biochem Behav26: 851–854.
51.
51 Brosnan CF, et al. (1985) Prazosin, an α1-adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat.Proc Natl Acad Sci USA, 82: 5915–5919.
52.
52 Goldmuntz EA, Brosnan CF, Norton WT. (1986) Prazosin treatment suppresses increased vascular permeability in both acute, passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol137: 3444–3450.
53.
53 Brosnan CF, et al. (1986) Prazosin treatment during the effector state of disease suppresses experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol137: 3451–3456.
54.
54 Claudio L, Brosnan CF. (1992) Effects of prazosin on the blood-brain barrier during experimental allergic encephalomyelitis. Brain Res594: 233–243.
55.
55 Hu X, Goldmuntz EA, Brosnan CF. (1991) The effect of norepinephrine on endotoxin-mediated macrophage activation. J Neuroimmunol31: 35–42.
56.
56 Spengler RN, et al. (1994) Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro. J Immunol152: 3024–3030.
57.
57 White SR, Black PC, Samathanam GK, Paros KC. (1992) Prazosin suppresses development of axonal damage in rats inoculated for experimental allergic encephalomyelitis. J Neuroimmunol39: 211–218.
58.
58 Chelmicka-Schorr E, Kwansiewski N, Thomas BE, Arnason BGW. (1989) The β-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol25: 203–207.
59.
59 Hoyer L, Good R, Condie R. (1962) Effect of 6-mercaptopurine in EAE. J Exp Med116: 311–327.
60.
60 Ridge SC, et al. (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol35: 35–42.
61.
61 Levine S, Saltzman A. (1986) Regional suppression therapy after onset, prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol13: 175–181.
62.
62 Lublin FD, Lavasa M, Viti C, Knobler RL. (1987) Suppression of acute, relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol45: 122–128.
63.
63 Watson CM, et al. (1991) Suppression of demyelination by mitoxantrone. Int J Immunopharmacol13: 923–930.
64.
64 Lu K, Savaraj N, Loo TL. (1984) Pharmacological disposition of 1, 4-dihydroxy-5-8-bis[2-(hydroxyethal) amino]ethyl amino]-9, 10 anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol13: 63–66.
65.
65 Unger C, et al. (1985) Blut-Hirnschranke und pentration von Zytostatika. Klin Wochenschr63: 565–571.
66.
66 Baker D, O'Neill JK, Davison AN, Turk JL. (1992) Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin Exp Immunol90: 124–128.
67.
67 Hall C, et al. (1989) Warning against use of intrathecal mitoxantrone. Lancet1: 734.
68.
68 Lakhani AK, et al. (1986) Warning against use of intrathecal mitoxantrone. Lancet2: 1393.
70 Calder V, et al. (1989) MS-a localised immune disease of the central nervous system. Immunol Today10: 99–103.
71.
71 Gonsette RE, Demonty L. (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for two years in 22 patients. Neurol40: (suppl1) 261.
72.
72 Cramer DV, et al. (1992) The effect of a new immunosuppressive drug, Brequinar sodium, on heart, liver, kidney allograft rejection in the rat. Transplant Proc24: 720–721.
73.
73 Schwartzmann G, et al. (1988) Pharmacokinetics of Brequinar sodium. (NSC 368390; DUP785) in cerebrospinal fluid. Eur J Cancer Clin Oncol24: 1903–1904.
74.
74 O'Neill JK, et al. (1992) Therapy of chronic relapsing experimental allergic encephalomyelitis, the role of the blood-brain barrier: elucidation by the action of Brequinar sodium. J Neuroimmunol38: 53–62.
75.
75 Davison AN, Levine S, Jaffee BD. (1991) Effects of Brequinar sodium on experimental allergic encephalomyelitis.Br J RheumatolXXX Suppl. No. 2: 83.
76.
76 Bolton C, Elderfield A-J, Flower RJ. (1990) The detection of lipocortins 1, 2, 5 in central nervous system (CNS) tissues from Lewis rats with experimental allergic encephalomyelitis (EAE). J Neuroimmunol29: 173–181.
77.
77 Elderfield A-J, Newcombe J, Bolton C, Flower RJ. (1992) Lipocortins. (Annexins) 1, 2, 4, 5 are increased in the central nervous system in multiple sclerosis. J Neuroimmunol39: 91–100.
79 Honegger CG, Krenger W, Langemann H. (1989) Changes in amino acid contents in the spinal cord, brain stem of rats with experimental autoimmune encephalomyelitis. J Neurochem53: 423–427.
80.
80 Sherman MP, Griscavage JM, Ignarro LJ. (1992) Nitric oxide-mediated neural injury in multiple sclerosis. Med Hypoth39: 143–146.
81.
81 Westarp ME, et al. (1987) T lymphocyte line-mediated experimental allergic encephalomyelitis — a pharmacological model for testing of immunosuppressive agents for the treatment of autoimmune central nervous system disease. J Pharmacol Exp Therap242: 614–620.
82.
82 Przuntek H, et al. (1987) The effect of silyl substituted methotrexate in the treatment of experimental allergic encephalomyelitis in rats mediated by T-line cells. Neuropharmacol26: 255–260.
83.
83 Desai S, Barton R. (1989) Pharmacological comparison of active, passive experimental allergic encephalomyelitis in the rat. Agents Actions27: 351–355.
84.
84 Nemoto K, et al. (1987) Suppression of experimental allergic encephalomyelitis in guinea pigs by spergualin, 15-deoxyspergualin.J AntibiotXL: 1193–1194.
85.
85 Schorlemmer HU, Seiler FR. (1991) 15-Deoxyspergualin. (15-DOS) for therapy in an animal model of multiple sclerosis. (MS): Disease modifying activity on acute, chronic relapsing experimental allergic encephalomyelitis. (EAE). Agents Actions34: 156–160.
86.
86 Willenborg DO, Parish CR, Cowden WB. (1989) Inhibition of experimental allergic encephalomyelitis by the α-glucosidase inhibitor castanospermine. J Neurol Sci90: 77–85.
